AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32041632
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D sufficient children (serum 25(OH)D > 20 ng/ml)
Trial: 34429160
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg BID + MTX
Trial: 34429160
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg every other week + MTX
Trial: 35289857
Drug: Tumor necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor necrosis factor inhibitors (TNFis) for at least 12 weeks
Trial: 34385272
Drug: BI 1265162
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1265162 200 µg twice daily
Trial: 32892245
Drug: Double-spin prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-spin prepared PRP injection
Trial: 32892245
Drug: Single-spin prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-spin prepared PRP injection
Trial: 32660025
Drug: Multi-strain probiotic
RxNorm normalized name: Digestive Advantage Multi-Strain Probiotic Ultra Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-strain probiotic (L. plantarum, L. bulgaricus, L. gasseri, B. breve, B. animalis sbsp. lactis, B. bifidum, S. thermophilus, and S. boulardii)
Trial: 33739404
Drug: Rd-R (lenalidomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rd-R (lenalidomide 10 mg per day without dexamethasone)
Trial: 35546664
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonists (albiglutide, exenatide, liraglutide, semaglutide, lixisenatide, dulaglutide)
Trial: 32375735
Drug: Primary surgery
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary surgery followed by systemic therapy
Trial: 32375735
Drug: Primary systemic
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary systemic therapy without surgery
Trial: 36378077
Drug: 150iu BD
RxNorm normalized name: BD
DrugBank: Butylene glycol (DB14110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150iu BD of formulated regular insulin in enteric-coated capsules
Trial: 36378077
Drug: 75iu BD
RxNorm normalized name: BD
DrugBank: Butylene glycol (DB14110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75iu BD of formulated regular insulin in enteric-coated capsules
Trial: 36378077
Drug: 300iu BD
RxNorm normalized name: BD
DrugBank: Butylene glycol (DB14110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300iu BD of formulated regular insulin in enteric-coated capsules
Trial: 35758031
Drug: Mirabegron (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron (300 mg daily)
Trial: 34136900
Drug: STIMULAX (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STIMULAX (oral Coloxyl® with senna and macrogol, with sodium phosphate enema for right-sided operations)
Trial: 35544473
Drug: Lipid/insulin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid/insulin infusion
Trial: 32464224
Drug: Higher-volume feedings
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-volume feedings (180-200 mL/kg/d)
Trial: 32464224
Drug: Usual-volume feedings
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual-volume feedings (140-160 mL/kg/d)
Trial: 35898121
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (topical numbing cream, positioning, and distraction by games on tablet/smartphone)
Trial: 34561291
Drug: Biomarker-directed treatment
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker-directed treatment adjustment
Trial: 34561291
Drug: Transition onto
RxNorm normalized name: Ontosein
DrugBank: Orgotein (DB11444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transition onto or off oral corticosteroids
Trial: 34561291
Drug: Prior study
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior study medication changes (two or more changes)
Trial: 33412106
Drug: FF/UMEC/VI 200/31·25/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/UMEC/VI 200/31·25/25 μg
Trial: 32203980
Drug: Deferasirox dispersible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox dispersible tablets (10 to 40 mg/kg per day)
Trial: 32798567
Drug: High early
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High early parenteral soybean oil lipid intake starting at 2 g/kg per day, increasing to 3 g/kg per day the following day.
Trial: 32798567
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group started at 0.5-1 g/kg per day, increasing daily by 0.5-1 g/kg per day till reaching 3 g/kg per day.
Trial: 34220819
Drug: Haemophilus influenzae‐type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus influenzae‐type b (Hib) vaccine
Trial: 33227803
Drug: Daily probiotic
RxNorm normalized name: CVS Daily Probiotic Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily probiotic milk (once daily)
Trial: 36447243
Drug: High-dose ECV19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ECV19 (20 μg RBD)
Trial: 36447243
Drug: Low-dose ECV19
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ECV19 (10 μg RBD)
Trial: 35449351
Drug: Clinical pharmacist-led
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacist-led stewardship program for appropriate use of acid suppression therapy
Trial: 32242396
Drug: Lingqi Huangban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lingqi Huangban granule (LQHB) plus intravitreal ranibizumab (IVR) injections
Trial: 34504129
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with optic nerve damage before treatment
Trial: 36327345
Drug: Computer based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer based cognitive therapy (CBCT)
Trial: 36091012
Drug: Mepolizumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (300 mg, subcutaneous, every 4 weeks)
Trial: 34698726
Drug: Short antibiotic
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short antibiotic prophylaxis (24 hours)
Trial: 34698726
Drug: Extended antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended antibiotic prophylaxis (7 days)
Trial: 36330836
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (four weeks of weekly questionnaires)
Trial: 32384147
Drug: Arginine therapy
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine therapy (100 mg/kg IV 3 times/day)
Trial: 32384147
Drug: Arginine therapy
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine therapy (loading dose 200 mg/kg then 100 mg/kg TID)
Trial: 32384147
Drug: Arginine therapy
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine therapy (loading dose 200 mg/kg followed by continuous infusion 300 mg/kg per day)
Trial: 32384147
Drug: Arginine therapy
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine therapy (all doses)
Trial: 34797272
Drug: Yoga-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga-based cognitive behavioral therapy (Y-CBT)
Trial: 34474163
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ST2 and REG3α
Trial: 35698203
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) group - loading dose of 1 μg/kg for 15 min and continuous infusion at 0.6 μg/kg/h until 30 min before the end of operation.
Trial: 35698203
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - normal saline infusion.
Trial: 35162346
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of plain 0.5% ropivacaine with perineurally added 1 mL/4 mg of dexamethasone (Group I)
Trial: 35162346
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of plain 0.5% ropivacaine with perineurally added 1 mL of 0.9% saline (Group II)
Trial: 35162346
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of plain 0.5% bupivacaine with perineurally added 1 mL of 0.9% saline (Group III)
Trial: 35934082
Drug: REGN1908/1909 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN1908/1909 600 mg
Trial: 34935603
Drug: VR training
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR training along with conventional physical therapy (CPT)
Trial: 36008108
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D treatment (50,000 IU bi-weekly)
Trial: 34798706
Drug: QLB-LSAL with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLB-LSAL with 0.5% ropivacaine (25 mL)
Trial: 34798706
Drug: TQLB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQLB with 0.5% ropivacaine (25 mL)
Trial: 33831611
Drug: Microsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microsurgical treatment (MST)
Trial: 32084522
Drug: High-dose spatially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose spatially fractionated radiation therapy (12 to 14 Gy via dose cylinders)
Trial: 32084522
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (external beam radiation therapy to the entire prostate and proximal seminal vesicles to 76 Gy at 2 Gy/fraction)
Trial: 34256607
Drug: Gabapentin (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1,200 mg/day)
Trial: 34460904
Drug: Antibiotic Stewardship
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic Stewardship Rounds (ASRs)
Trial: 34033975
Drug: Tislelizumab plus
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab plus chemotherapy (platinum and pemetrexed)
Trial: 34033975
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (platinum and pemetrexed)
Trial: 39738721
Drug: Tislelizumab plus
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab plus chemotherapy
Trial: 35653758
Drug: Hearing emotion
RxNorm normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hearing emotion labels before sorting (e.g., 'happy faces go here')
Trial: 35653758
Drug: Not given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not given labels (e.g., 'faces like this go here')
Trial: 33536102
Drug: Simvastatin (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10-20 mg/day)
Trial: 33536102
Drug: Captopril (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (0.2 mg/kg/day)
Trial: 35037116
Drug: Berberine (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine (900 mg/day)
Trial: 32746774
Drug: 200g of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200g of cod twice a week for 16 weeks
Trial: 33253318
Drug: Baseline visceral-to-subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline visceral-to-subcutaneous fat ratio (VFR)
Trial: 35404227
Drug: Propranolol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol administered orally 60 to 75 minutes prior to psychotherapeutic sessions
Trial: 33831625
Drug: Surgical dressing
RxNorm normalized name: SURGICAL DRESSINGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical dressing changed twice a week (HMO)
Trial: 33105353
Drug: β-Alanine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-Alanine (12 g/d for 14 days)
Trial: 34155637
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy (8 sessions)
Trial: 34155637
Drug: Wait list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait list control (8 sessions of behavior therapy after wait list)
Trial: 34196442
Drug: Tapentadol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol (50 mg extended release)
Trial: 34196442
Drug: Oxycodone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (10 mg extended release)
Trial: 37702920
Drug: Sotrovimab 500
RxNorm normalized name: sotrovimab 500 MG in 8 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotrovimab 500 mg
Trial: 34953520
Drug: BRII-196 plus
RxNorm normalized name: pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRII-196 plus BRII-198 (1000 mg each)
Trial: 33319566
Drug: Ganoderma lucidum
RxNorm normalized name: GANODERMA LUCIDUM STEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganoderma lucidum (GL) 6 g/day for 6 weeks
Trial: 33319566
Drug: Ceratonia siliqua
RxNorm normalized name: CERATONIA SILIQUA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceratonia siliqua (CS) 6 g/day for 6 weeks
Trial: 34644395
Drug: Post-treatment MRI
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment MRI showing 100% fibrotic fistula
Trial: 34644395
Drug: Post-treatment MRI
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment MRI MAGNIFI-CD index
Trial: 34644395
Drug: Degree of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degree of fibrosis at post-treatment MRI
Trial: 34644395
Drug: MAGNIFI-CD index
RxNorm normalized name: INSULIN MAGNIFIER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAGNIFI-CD index at post-treatment MRI
Trial: 34047292
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without root canal preparation).
Trial: 33823815
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of 300 ml carbohydrate solution (CH group)
Trial: 33823815
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of 300 ml pure water (PW group)
Trial: 36345697
Drug: Hydroquinone 2%
RxNorm normalized name: HYDROQUINONE 2% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroquinone 2% cream + 755-nm picosecond laser
Trial: 36345697
Drug: Hydroquinone 2%
RxNorm normalized name: HYDROQUINONE 2% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroquinone 2% cream alone
Trial: 34610971
Drug: Doxorubicin 50
RxNorm normalized name: DOXOrubicin 50 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m2 and lurbinectedin 3.0-5.0 mg (escalation phase)
Trial: 34610971
Drug: Doxorubicin 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 40 mg/m2 and lurbinectedin 2.0 mg/m2 (expansion cohort)
Trial: 34429127
Drug: Aspirin, orally,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, orally, 85-150 mg daily for 35 days after HA and 14 days after KA
Trial: 34429127
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH, enoxaparin), 40 mg, subcutaneously, daily within 24 hours postoperatively for 35 days after HA and 14 days after KA
Trial: 32776763
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (superficial heat, transcutaneous electrical nerve stimulation, pulsed ultrasound)
Trial: 32776763
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin type A (single intra-articular injection)
Trial: 32776763
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (three intra-articular injections)
Trial: 32776763
Drug: 20% dextrose
RxNorm normalized name: Aminosyn II 4.25% in 20% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% dextrose (three intra-articular injections)
Trial: 35640598
Drug: High Brazilian
RxNorm normalized name: BRAZILIAN PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Brazilian green propolis dose (H‐BGP)
Trial: 35640598
Drug: Low Brazilian
RxNorm normalized name: BRAZILIAN PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Brazilian green propolis dose
Trial: 32105342
Drug: Total magnesium
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total magnesium intake (diet + supplements)
Trial: 34259406
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received comprehensive therapy of eye covering of intact side and family refined performance
Trial: 34916319
Drug: Psychotropic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic medication use
Trial: 33106696
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care
Trial: 35964471
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg every 2 weeks for 4 doses and then every 12 weeks, intravenously ≤1 year
Trial: 35964471
Drug: Ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 10 mg/kg every 3 weeks for 4 doses and then every 12 weeks, intravenously ≤1 year
Trial: 32554837
Drug: Qurs-e-Gulnar, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qurs-e-Gulnar, 3 Qurs twice a day for 45 days
Trial: 32554837
Drug: Diabeat®, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabeat®, 2 capsules twice a day for 45 days
Trial: 32867965
Drug: FSE diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSE diet (basal diet + 100 mg/kg FSE)
Trial: 32217275
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment and home exercise program (HEP)
Trial: 33726537
Drug: Topical Nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Nepafenac
Trial: 36332827
Drug: Psilocybin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (25 mg/70 kg)
Trial: 36332827
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo (50 mg diphenhydramine)
Trial: 35794485
Drug: Synergistic mindsets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synergistic mindsets intervention (self-administered online training module)
Trial: 36652353
Drug: BNT162b2 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 (30 μg)
Trial: 36399969
Drug: Half-dose mRNA-1273
RxNorm normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose mRNA-1273 (50 μg)
Trial: 36376733
Drug: mRNA-1273 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (100 μg)
Trial: 36399969
Drug: MVC-COV1901 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVC-COV1901 (15 μg)
Trial: 36399969
Drug: All booster
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All booster vaccines
Trial: 38012751
Drug: mRNA vaccines
RxNorm normalized name: ChulaCov19 mRNA vaccine
DrugBank: ChulaCov19 mRNA vaccine (DB16445)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA vaccines
Trial: 32273122
Drug: Stick™ resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stick™ resin treatment
Trial: 32273122
Drug: Ethylene glycol
RxNorm normalized name: ethylene glycol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethylene glycol + triazabicyclodecene treatment
Trial: 32336148
Drug: AbobotulinumtoxinA (⩽5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AbobotulinumtoxinA (⩽5 treatment cycles) in the upper limb
Trial: 32336148
Drug: AbobotulinumtoxinA (⩽5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AbobotulinumtoxinA (⩽5 treatment cycles) in the lower limb
Trial: 32336148
Drug: AbobotulinumtoxinA (⩽5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AbobotulinumtoxinA (⩽5 treatment cycles)
Trial: 32339253
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m2 on day 1, 8, and 15) plus everolimus (10 mg daily, arm B)